SAFETY SIGNALS MATTER AS SEMAGLUTIDE SCALES

THE global weight-loss treatment market has not had it so good in ages.

- 

From a ‘class’ drug priced at a prohibitive ₹10,000 a month and above, the jab’s cost dropped by as much as 70-90 percent in a day, potentially making it massy. It all happened on March 21, a day after Danish pharma major Novo Nordisk’s patent protection for its blockbuster diabetes and weight-loss drug, Semaglutide, expired in India. The domestic industry, which specialises in low-cost knockoffs, populated the market quickly with its generic variants. Initially marketed by innovator Nordisk as an active pharma ingredient for managing Type 2 diabetes, Semaglutide later became popular as a tool to control obesity. For example, Semaglutide is the core ingredient in Ozempic, one of Nordis